| Name | Title | Contact Details |
|---|
InnoTraction is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SWORD Health is the world`s fastest growing virtual musculoskeletal (MSK) care provider, on a mission to free two billion people from chronic and post-surgical pain. The company`s clinical-grade virtual therapy platform pairs expert physical therapists with FDA-listed wearable technology to deliver a personalized treatment plan that is more effective, easier and less expensive than traditional physical therapy. SWORD Health believes in the power of people to recover at home, without resorting to imaging, surgeries or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems and employers in the U.S, Europe and Australia to make quality physical therapy more accessible to everyone. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney and Porto.
Nicoya is a Canadian biotechnology company dedicated to improving human life by helping scientists succeed. Established in 2012, Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. ...
24 Hour Emergency Room is a Tomball, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.